Home » Market News » DirectorsTalk Highlights » INTERVIEW: OptiBiotix Health Plc – An exciting time for investors
Optibiotix Health Plc

INTERVIEW: OptiBiotix Health Plc – An exciting time for investors

OptiBiotix Health Plc (LON:OPTI) CEO Stephen O’Hara talks to DirectorsTalk about the listing of SkinBiotheraputics (LON:SBTX). Stephen explains the rationale behind the launch, what this could mean for OptiBiotix investors, the timing involved and how this all fits into the company strategy.

OptiBiotix Health plc has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

SkinBioTherapeutics is a life science company focused on skin health. The Company’s proprietary platform technology, SkinBiotix™, is based upon discoveries made by CEO Dr. Catherine O’Neill and Professor Andrew McBain. The company is targeting three specific markets; cosmetics, infection control and eczema. In each of these areas the Company intends to exemplify its technology in human studies.  The most advanced programme is focused on creating an ingredient for the cosmetics industry to treat sensitive skin. The business strategy is to outlicense its programmes at proof of concept.

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.